Preventive treatment of multiple sclerosis. Rules for treatment with immuno-modulators;Tratamiento preventivo en la esclerosis múltiple. Normas para el tratamiento con inmunomoduladores

Revista de Neurologia

Volumn 35, Issue 11, 2002, Pages 1094-1099

  Izquierdo, Guillermo ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

Cerebrospinal fluid; Immuno modulators; Magnetic ressonance; Multiple sclerosis; Remitting relapsing form

Indexed keywords

BETA1A INTERFERON; IMMUNOMODULATING AGENT; MITOXANTRONE;

CEREBROSPINAL FLUID EXAMINATION; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; FEMALE; HUMAN; LIFE EXPECTANCY; MALE; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRESCRIPTION; PROGNOSIS; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0036970752     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3511.2002384     Document Type: Review

References (27)

1. Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000; 48: 885-92.
2. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61
3. The IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon b-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85.
4. Paty DW, Li DK, University of British Columbia MS/MRI Analysis Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-7.
5. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268-76.
6. Comi G, Filippi M, Wolinsky JS, European/Canadian Glatimer Acetate Study Group. European/Canadian multicenter, double blind, randomized, placebo-controlled study of the effects of glatimer acetate on magnetic resonance imagingmeasured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290-7.
7. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-94.
8. PRISMS (Prevention of Relapses and Disability by Interferon b-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504. [Erratum, Lancet 1999; 353: 678]
9. Fazekas F, Deisenhammer F, Strasser-Fuschs S, Nahaler G, Mamoli B. Randomized placebo-controlled trial of monthly intravenous therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin Multiple Sclerosis Study Group. Lancet 1997; 349: 589-93.
10. Francis G, Freedman M, Antel J. Failure of intravenous immunoglobulin to arrest progression in of multiple sclerosis: a clinical and MRI based study. Mult Scler 1997; 3: 370-6.
11. Noseworthy JH, O'Brien PC, Weinshenker BG, Weis JA, Petterson TM, Erickson BJ, et al. IV immunoglobulin does not reverse established weakness in MS. Double blind. Placebo-controlled trial. Neurology 2000; 55: 1135-43.
12. European Study Group on Interferon b-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon b-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7.
13. Miller DH, Molyneux PD, Barker GJ, MacManus DG, Mosele IF, Wagner K. Effect of interferon b-1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of an European multicenter, randomized, double-blind, placebo-controlled trial. Ann Neurol 1999; 46: 850-9.
14. Goodkin DE, North American Study Group on Interferon beta-1b in Secondary Prevention MS. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial [abstract]. Neurology 2000; 54 (Suppl): 2352.
15. Paty D. Results of the 3-year, double-blind, placebocontrolled study of interferon beta-1a (Rebif) in secondaryprogressive MS. Presented at the Ninth Annual Meeting of the European Neurological Society, Milan, Italy; 1999.
16. Hughes R, SPECTRIMS Group. 'Relapsing' versus 'nonrelapsing' SPMS: different prognosis and response to interferon therapy in the SPECTRIMS study [abstract]. Neurology 2000; 54 (Suppl 3): A233.
17. Leary SM, Miller DH, Stevenson VL, Thompson AJ. Interferon beta-1a in primary progressive multiple sclerosis; results of phase II double-blind, placebo controlled trial. Rev Neurol (Paris) 2000; 156 (Suppl 3): S39.
18. Montalbán X. Immunomodulating treatment in PP MS. Rev Neurol (Paris) 2000; 156 (Suppl 3): S18.
19. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898-904.
20. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112: 133-46.
21. Comi G, Filippi M, Barkhof F, et al. Interferon beta-1a (Rebif) in patients with acute neurological syndromes suggestive of multiple sclerosis: a multicenter, randomized, double-blind, placebo-controlled study [abstract]. Neurology 2000; 54 (Suppl 3): A85-6.
22. Izquierdo G, Hauw JJ, Lyon-Caen O, Marteau R, Escourolle R, Buge A, et al. Analyse clinique de 70 cas neuro-pathologiques de sclerose en plaques. Rev Neurol (Paris) 1985; 141: 546-52.
23. Clanet M. Interferon beta-1a (Avonex) dose-comparison study. Searching for the truth. MS treatment. Paris; 2001. [Abstract 4-5].
24. Radue EW. MRI data of multicenter doble blind dose-comparison trial of 30 vs 60 mcg interferon beta-1a (Avonex) in patients with relapsing remitting multiple sclerosis. Searching for the truth. Paris; 2001. [Abstract 6-7].
25. Fernández O, Antigüedad A, Arbizu T, Burgués S, Capdevila A, de Castro P, et al. El interferón beta natural en el tratamiento de la esclerosis múltiple recurrente remitente: un ensayo clínico de fase II, multicéntrico, aleatorio y controlado por RM. Rev Neurol 1999; 29: 1093-9.
26. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnosis criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
27. The Once Weekly Interferon for MS Study Group (OWIMS). Evidence of interferon b-1a dose response in relapsing-remitting MS. The OW-IMS study. Neurology 1999; 53: 679-86.